Alzheimer's disease; taking the edge off with cannabinoids?

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline, beta-amyloid plaques, and tau hyperphosphorylation.
• Neuroinflammation, oxidative stress, and excitotoxicity are key pathological features of AD.
• The endocannabinoid system is altered in Alzheimer's patients, suggesting its involvement in disease pathophysiology.

Purpose of the Study:

• To review the neuroprotective potential of cannabinoids in Alzheimer's disease.
• To explore how cannabinoids may mitigate AD symptoms and progression.
• To evaluate the cannabinoid system as a therapeutic target for AD.

Main Methods:

• Review of existing literature on cannabinoids and Alzheimer's disease.
• Analysis of studies investigating cannabinoid effects on beta-amyloid and tau pathology.
• Examination of research on cannabinoid-induced neuroprotection, anti-neuroinflammation, and neurogenesis.

Main Results:

• Cannabinoids protect neurons from beta-amyloid toxicity and reduce tau phosphorylation.
• Cannabinoids mitigate oxidative stress and neurodegeneration associated with beta-amyloid.
• Delta 9-tetrahydrocannabinol can inhibit acetylcholinesterase and limit amyloidogenesis.
• Targeting cannabinoid receptors may reduce neuroinflammation without psychoactive effects.

Conclusions:

• Cannabinoids offer a multi-faceted therapeutic strategy for Alzheimer's disease.
• They provide neuroprotection, reduce neuroinflammation, and support intrinsic brain repair mechanisms.
• The cannabinoid system presents a promising therapeutic target for Alzheimer's disease treatment.